Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | POLB | P06746 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1877246 | 0.98 | KMT2A (0.80) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL4724436 | 0.95 | KMT2A (0.75) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL9152022 | 0.91 | CA12 (0.77) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL4689720 | 0.89 | KMT2A (0.68) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL27971693 | 0.86 | CA12 (0.70) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL142197 | 0.85 | CA12 (0.68) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL28866336 | 0.85 | CA12 (0.64) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL4039721 | 0.85 | KMT2A (0.65) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL19313021 | 0.83 | CA12 (0.67) | KMT2APOLBMEN1ALDH1A1HPGD | |
| SCHEMBL110101 | 0.83 | ALDH1A1 (0.72) | KMT2APOLBMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11712458-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-111423396-B | sEH inhibitor, and preparation method and application thereof | 沈阳药科大学 | 2023-01-06 | — | — | CN | disclosed |
| US-20220177416-A1 | PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINE | Research & Business Foundation Sungkyunkwan University (KR) | 2022-06-09 | — | — | US | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732073-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170209441-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | UNIVERSITY OF DELHI (IN) | 2017-07-27 | — | — | US | disclosed |
| US-9567316-B2 | Aminoquinoline derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2017-02-14 | — | — | US | disclosed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212318-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016130-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | KMT2A 2176/4885POLB 1808/4885MEN1 2916/4885 |
| US-11712458-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | KMT2A 899/4885POLB 2261/4885MEN1 4259/4885 |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | KMT2A 958/4885POLB 2450/4885MEN1 2745/4885 |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | KMT2A 2638/4885POLB 1037/4885MEN1 3157/4885 |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | KMT2A 2638/4885POLB 1037/4885MEN1 3157/4885 |
| US-20220177416-A1 | PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINE | TYR, NAT1, SAT1 | KMT2A 141/4885POLB 393/4885MEN1 1585/4885 |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | KMT2A 1009/4885POLB 1989/4885MEN1 4114/4885 |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | KMT2A 1009/4885POLB 1989/4885MEN1 4114/4885 |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | KMT2A 958/4885POLB 2450/4885MEN1 2745/4885 |
| US-20170209441-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | LRRK2, NLRP3, AADAT | KMT2A 1108/4885POLB 2467/4885MEN1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.